In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-AgaMatrix Deal a Harbinger

Executive Summary

Sanofi-Aventis is allying with AgaMatrix around the latter's blood glucose monitoring technology. The deal gets Sanofi a BGM product line and access to a technology around which it can begin to build an integrated diabetes management system. Importantly, it signals to other companies that it is moving in that direction. That could help Sanofi in partnering or M&A discussions around other aspects of diabetes device development, including continuous glucose monitoring, and also stimulate competitors to pick up the deal-making pace.
Advertisement

Related Content

Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Merck Adds To Diabetes Franchise With SmartCells Acquisition
Cellnovo's Mobile Health Approach to Diabetes Care
Continuous Glucose Monitoring: A Case Study for Commercializing Products In The Era of Patient-Driven Health Care
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
Where are They Now? Checking in on Three Glucose-Monitoring Start-Ups
Abbott/TheraSense: A Subtext Beyond the Diabetes Market?
TheraSense's Sweet Spot
TheraSense's Sweet Spot

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel